Expression of G1-S modulators (p53, p16, p27, cyclin D1, Rb) and Smad4/Dpc4 in intrahepatic cholangiocarcinoma

Yun Kyung Kang1, Woo Ho Kim, Ja June Jang

  • 1Department of Pathology, Inje University Seoul Paik Hospital and Seoul National University College of Medicine, Korea.

Human Pathology
|October 16, 2002
PubMed

Insights

Aberrations in the G1-S cell cycle arrest and TGF-beta/Smad pathways are key to human cancer development. These alterations are frequent in intrahepatic cholangiocarcinomas and correlate with advanced disease stages.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gastroenterology

Background:

  • Aberrations in cell cycle regulation (G1-S arrest) and the TGF-beta/Smad pathway are implicated in human carcinogenesis.
  • Intrahepatic cholangiocarcinoma (ICC) is a complex malignancy where these pathways may play a significant role.

Purpose of the Study:

  • To investigate the alterations in G1-S cell cycle arrest and TGF-beta/Smad pathways in intrahepatic cholangiocarcinomas (ICCs).
  • To correlate these molecular changes with clinicopathological features and disease progression.

Main Methods:

  • Immunohistochemical staining was performed on 42 ICC tissue samples to assess the expression of p53, p16, p27, cyclin D1, Rb, and Smad4.
  • Analysis included evaluation of adjacent biliary dysplasia for similar molecular alterations.

Main Results:

  • High frequencies of abnormalities were observed: p53 (35.7%), cyclin D1 (61.9%), p16 loss (35.7%), p27 loss (31.0%), Rb loss (11.9%), and Smad4 loss (45.2%).
  • Ninety-five percent of ICCs exhibited alterations in at least one pathway, with 50% showing G1-S pathway abnormalities only, 40.5% in both, and 4.8% in TGF-beta/Smad only.
  • Loss of Smad4 correlated with advanced pTNM stage (P < 0.05).
  • A higher number of gene alterations (2-5) was associated with significantly higher tumor stage (P < 0.01).
  • Abnormal expression of p53, cyclin D1, or p16 was found in 7 of 13 dysplastic lesions.

Conclusions:

  • Altered G1-S cell cycle regulation and TGF-beta/Smad signaling are critical events in cholangiocarcinogenesis.
  • A cumulative effect of these molecular alterations may influence the clinical outcome in patients with resectable ICCs.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...